Press Room

2021 AIChE Annual meeting

Start
Monday, November 15, 2021 - 00:00
End
Monday, November 15, 2021 - 00:00
Location: Online
Hovione present at AICHE with scientific presentations

Meet Hovione Scientists virtually at 2021 AIChE Annual Meeting and find their exciting presentations on the latest research and innovations:

 

Date: November 15th, 2021

Title: Enabling Continuous Antisolvent Crystallization Using Hollow Fibre Membranes
Author: António Henriques, Rui César

Session: Virtual Crystallization and Evaporation Talks

Date: November 16th, 2021

Title: Process Safety Evaluation and Scale-up Resorting to Mechanistic Modelling for Exothermic and Gas Release Reactions
Author: Filipe Ataíde

Session: Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals and Biopharmaceuticals

Title: Reaction Kinetic Modelling Coupled with Process Safety Calorimetry for Effective Scale-up of an Exothermic Reaction
Author: Filipe Ataíde

Session: Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals and Biopharmaceuticals

Date: November 18th, 2021

Title: Spray-Dried Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Performance
Author: Patrícia Henriques

Session: Advances in Drug Discovery and Drug Delivery

 

Schedule a meeting with our experts

We will work together to ensure successful scale-up even with the tightest development timelines

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024